drug · small molecule

SINEMET

updated 3mo ago

by $OGN Organon & Co.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 24 investigational indications.

targets

Aromatic-L-amino-acid decarboxylase

all catalysts(0)

nothing on the calendar yet

Trials studying SINEMET

phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuationscompletedn=165
phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participantsrecruitingn=12
phase1Relative Bioavailability Study of HRG2010 in Healthy Subjectscompletedn=16
—Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Diseaseactive not recruitingn=100
phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuationscompletedn=61
phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patientscompletedn=8
phase2Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopacompletedn=20
phase1A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjectscompletedn=35

more trials →

News(0)

no news has mentioned this drug yet

brand

SINEMET

trade names

Carbidopa, Carbidopa component of corbilta, Carbidopa component of crexont, Carbidopa component of dhivy, Carbidopa component of dopasnap, Carbidopa component of duopa

generic

CARBIDOPA

MOA

Mechanism of Action Parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Symptomatic treatments, such as levodopa therapies, may permit the patient better mobility. Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

indication

INDICATIONS AND USAGE SINEMET is indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on SINEMET. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 36m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

SINEMET

updated 3mo ago

by $OGN Organon & Co.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 24 investigational indications.

targets

Aromatic-L-amino-acid decarboxylase

all catalysts(0)

nothing on the calendar yet

Trials studying SINEMET

phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuationscompletedn=165
phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participantsrecruitingn=12
phase1Relative Bioavailability Study of HRG2010 in Healthy Subjectscompletedn=16
—Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Diseaseactive not recruitingn=100
phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuationscompletedn=61
phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patientscompletedn=8
phase2Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopacompletedn=20
phase1A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjectscompletedn=35

more trials →

News(0)

no news has mentioned this drug yet

brand

SINEMET

trade names

Carbidopa, Carbidopa component of corbilta, Carbidopa component of crexont, Carbidopa component of dhivy, Carbidopa component of dopasnap, Carbidopa component of duopa

generic

CARBIDOPA

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 36m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

SINEMET

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying SINEMET

News(0)

Report a data issue

comments(0)

SINEMET

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying SINEMET

News(0)

Report a data issue

comments(0)